Healthcare
Raphael Pharmaceutical Inc.(RAPH)
Live Price
Offline$1.40
+0.00% today
1Y Change
+536.36%
Window
Jun 23, 2025 โ Jun 11, 2026
- Market Cap
- $30.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +186.1%
- Dividend Yield
- 0.0%
Coverage: 241 bars ยท Jun 23, 2025 โ Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Raphael Pharmaceutical Inc. (RAPH) is a Healthcare stock with a market cap of $30.00M and listed on OTC. The stock last traded around $1.40 and up 536.4% across the available one-year price window (Jun 23, 2025 โ Jun 11, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +186.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +186.1%, free cash flow +60.5% with operating margin 0.0% and ROIC 79.1%. Stock Foundry combines RAPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 31, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +186.1%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 31, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Nov 13, 2025 | โ | +0.0% | +0.0% | +40.0% |
2025 Aug 13, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RAPH
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RAPH Max Drawdown
-97.14%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RAPH and SPY.
Company Overview
Raphael Pharmaceutical Inc.
Other OTC
Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases. The company is headquartered in Tel Aviv-Jaffa, Israel.
- Leadership
- Shlomo Pilo
- IPO Date
- Jan 5, 2023
- Street Address
- 4 Lui Paster
- Mailing
- Jaffa, 6803605
- Region
- Jaffa, IL
- Reporting Currency
- USD
- Investor Line
- 972 5 2775 5072
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +186.1%
- Free Cash Flow
- +60.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 102.3%
- ROIC
- 79.1%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.